---
id: sgkb.consumer.proposed-complementary-health-products-regulation-2026
kind: article
title: "Proposed Complementary Health Products Regulation"
url: https://ik.sg/en/knowledge/article/sgkb.consumer.proposed-complementary-health-products-regulation-2026
language: en
evidence_status: verified
last_verified: 2026-10-24
collection_as_of: 2026-11-22
---

# Proposed Complementary Health Products Regulation

HSA's 2026 proposal would move remaining complementary-health-product controls to the Health Products Act while keeping light-touch pre-market regulation and adding notification and traceability requirements.

# Proposed Complementary Health Products Regulation

The Health Sciences Authority (HSA) consulted on a proposed regulatory framework for **Complementary Health Products (CHP)** under Singapore's Health Products Act. The consultation ran from **1 to 29 July 2026**. HSA describes the proposal as a future framework, not enacted amendments already applying to every CHP ([HSA, 1 July 2026](https://www.hsa.gov.sg/announcements/consultation-proposed-regulation-complementary-health-products/)).

## Products and current baseline

HSA describes CHP as self-care products containing ingredients with a long history of safe use, intended to support general health or alleviate minor symptoms consumers can manage themselves. The consulted categories include health supplements, traditional medicines excluding traditional Chinese medicines, homeopathic medicines, medicated oils, balms and plasters, and topical antiseptics ([HSA, 1 July 2026](https://www.hsa.gov.sg/announcements/consultation-proposed-regulation-complementary-health-products/)).

At the time of consultation, CHP were regulated under the Medicines Act with a light-touch approach: they were not subject to pre-market product evaluation or licensing of manufacturers, importers and suppliers, although HSA imposed safety and quality requirements and used post-market surveillance. HSA separately stated that traditional Chinese medicinal products would follow a separate Health Products Act framework from early 2027 ([HSA, 1 July 2026](https://www.hsa.gov.sg/announcements/consultation-proposed-regulation-complementary-health-products/)).

## Proposed controls

HSA proposed moving the remaining medicinal-product controls in the CHP scope from the Medicines Act to the Health Products Act by the end of **2028**. The proposal would maintain light-touch pre-market controls while strengthening product safety, quality and labelling requirements and the duties of manufacturers, importers and suppliers ([HSA, 1 July 2026](https://www.hsa.gov.sg/announcements/consultation-proposed-regulation-complementary-health-products/)).

The consultation covered six areas: product notification; product safety and quality; product labelling; record keeping and safety reporting; advertisement controls; and the implementation timeline. HSA also proposed that a person instrumental in placing a CHP on the local market notify HSA of key product information, supporting traceability, post-market surveillance and timely regulatory action when safety issues are detected ([HSA, 1 July 2026](https://www.hsa.gov.sg/announcements/consultation-proposed-regulation-complementary-health-products/)).

## Interpretation boundary

This proposal should not be confused with HSA's existing List of Notified Complementary Health Products. That list records voluntary company notifications and is not HSA product approval or endorsement ([HSA, List of Notified Complementary Health Products](https://www.hsa.gov.sg/other-regulations/vns-list/), page last updated 21 October 2026). The 2026 consultation concerned a possible statutory framework; its consultation date and proposed end-2028 migration plan do not prove that the final rules, scope or commencement will be identical to the proposal.

The distinction is especially important for consumers and businesses using the words “registered”, “notified” or “approved”. HSA's current list is based on voluntary company declarations against published guidelines, whereas the consultation proposed future statutory notification and traceability duties; neither wording alone establishes that HSA has assessed a product's therapeutic effectiveness ([HSA, notified products, page last updated 21 October 2026](https://www.hsa.gov.sg/other-regulations/vns-list/); [HSA, consultation page last updated 23 October 2026](https://www.hsa.gov.sg/announcements/consultation-proposed-regulation-complementary-health-products/)).

## Status and practical interpretation

The consultation closed on **29 July 2026**. As checked on **24 October 2026**, the consultation page (last updated 23 October) still presents the proposal and its end-2028 intention, but does not state a post-consultation decision or commencement date. HSA's current CHP overview (last updated 9 September) continues to describe dealer safety, quality and labelling responsibilities and voluntary notification ([HSA consultation](https://www.hsa.gov.sg/announcements/consultation-proposed-regulation-complementary-health-products/); [HSA, Complementary health products](https://www.hsa.gov.sg/other-regulations/chp/)). On the material those pages publish, the consultation proposals must not be described as enacted or commenced requirements. A product appearing on the voluntary list therefore does not demonstrate that the proposed Health Products Act controls have commenced, that HSA has evaluated the product for efficacy, or that the product may make disease-treatment claims. For a current compliance decision, identify the product category, the applicable operative legislation and the latest HSA guidance rather than relying on the consultation proposal alone.

## Sources

- [HSA — Stakeholder Consultation on the Proposed Regulation for Complementary Health Products](https://www.hsa.gov.sg/announcements/consultation-proposed-regulation-complementary-health-products/) — Accessed 2026-10-24
- [HSA — List of Notified Complementary Health Products](https://www.hsa.gov.sg/other-regulations/vns-list/) — Accessed 2026-10-24
- [HSA — Complementary health products: current controls](https://www.hsa.gov.sg/other-regulations/chp/) — Accessed 2026-10-24

## Explore connections

- Articles: [HSA List of Notified Complementary Health Products](https://ik.sg/en/knowledge/article/sgkb.consumer.hsa-notified-complementary-health-products)
- Topics: [Consumer affairs](https://ik.sg/en/knowledge/topic/sgtopic.consumer)
- Topics: [Proposed Complementary Health Products Regulation](https://ik.sg/en/knowledge/topic/sgtopic.consumer.proposed-complementary-health-products-regulation-2026)
- People & organisations: [Health Sciences Authority](https://ik.sg/en/knowledge/entity/sg.agency.hsa)
- People & organisations: [HSA List of Notified Complementary Health Products](https://ik.sg/en/knowledge/entity/sg.list.hsa-notified-complementary-health-products)
- People & organisations: [Proposed Complementary Health Products Framework](https://ik.sg/en/knowledge/entity/sg.regulation.proposed-chp-framework-2026)

Dates describe this record’s own period and applicability. A verification date does not mean a rule is currently in force. An expanding collection. Published counts show available knowledge, not complete coverage of Singapore.
